From: Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
Variable | CGC n = 12 | CyGC n = 20 | P* |
---|---|---|---|
PAD (mg/patient) | |||
8 weeks | 4200 | 1500 | - |
12 weeks | - | 2500 | - |
Fasting hyperglycemia (≥5.60 mmol/L) | |||
Incidence, n (%) | 12 (100) | 10 (50) | 0.003* |
Plasma glucose (mmol/L) | 8.22 ± 3.79 | 6.50 ± 0.64 | 0.16 |
Prediabetes (≥5.60- < 7.00 mmol/L) | |||
Incidence, n (%) | 5 (41.6) | 6 (30) | 0.51 |
DM (fasting glycemia ≥7.00 mmol/L) | |||
Incidence, n (%) | 7 (58.3) | 4 (20) | 0.22 |
Plasma glucose (mmol/L) | 9.83 ± 4.39 | 7.11 ± 0.15 | 0.26 |
DM occurrence - week, n (%) | |||
First | 0 (0) | 0 (0) | - |
Second to fourth | 5 (71.4) | 0 (0) | - |
Fifth to eighth | 2 (28.5) | 4 (100) | - |
Postprandial hyperglycemia | |||
Incidence, n (%) | 1 (8.3) | 4 (20) | 0.62 |